Drugs / DWP213388
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05607589 | Oct 2022 → Feb 2024 | — | Daewoong Pharmaceutical Co. LTD. | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-08-19 | Daewoong Pharmaceutical Co. LTD. | Regulatory Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-in-class Irreversible Oral Dual Acting inhibitor for Autoimmune Diseases daewoong.co.kr ↗ |
| 2019-12-12 | Daewoong Pharmaceutical Co. LTD. | Results Daewoong Pharmaceutical Publishes Research Outcomes of Autoimmune Disease Candidate DWP213388 in the American Society of Hematology daewoong.co.kr ↗
Daewoong Pharmaceutical(Daewoong, CEO Sengho Jeon) unveiled the research outcomes of autoimmune disease candidate DWP213388 for the first time in the 2019 American Society of Hematology (ASH) Annual Meeting held on Dec. 9 (local time), which garnered much attention. |
| 2018-11-28 | Daewoong Pharmaceutical Co. LTD. | Results Daewoong Pharmaceutical presents its research results on ‘treatments for fibrosis and autoimmune disease’ at ACR daewoong.co.kr ↗
The result of pre-clinical trial on DWP213388 was first revealed as well. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-28 | Daewoong Pharmaceutical Co. LTD. | Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio daewoong.co.kr ↗ |
| 2022-08-19 | Daewoong Pharmaceutical Co. LTD. | Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-in-class Irreversible Oral Dual Acting inhibitor for Autoimmune Diseases daewoong.co.kr ↗ |
| 2019-12-12 | Daewoong Pharmaceutical Co. LTD. | Daewoong Pharmaceutical Publishes Research Outcomes of Autoimmune Disease Candidate DWP213388 in the American Society of Hematology daewoong.co.kr ↗ |
| 2018-11-28 | Daewoong Pharmaceutical Co. LTD. | Daewoong Pharmaceutical presents its research results on ‘treatments for fibrosis and autoimmune disease’ at ACR daewoong.co.kr ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWP213388 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05607589 ↗ |
| Route | Oral | “The administration will be a single or multiple oral doses for healthy subjects.” NCT05607589 ↗ |